The potential for monocyte-mediated immunotherapy during infection and malignancy - Part II: In vivo activation by exogenous cytokines and clinical applications

Leukemia and Lymphoma

Volumn 34, Issue 3-4, 1999, Pages 207-230

  Williams, Marc A ^a   Rhoades, Christopher J ^a   Newland, Adrian C ^a   Kelsey, Stephen M ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Granulocyte macrophage colony stimulating factor; Immunotherapy; Infection; Inflammation; Malignancy; Monocyte

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; CD14 ANTIGEN; CD16 ANTIGEN; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3;

ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; HELPER CELL; HUMAN; IMMUNOTHERAPY; INFECTION; MACROPHAGE ACTIVATION; MONOCYTE; PRIORITY JOURNAL; REVIEW; SEPSIS;

EID: 0032873091     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199909050947     Document Type: Review

References (123)

1. Bone RC Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: What we do and do not know about cytokine regulation [Review]. Crit Care Med 24: 163-72, 1996.
2. Ostermann H, Rothenburger M, van de Loo J, Kienast J. Cytokine response to infection in patients with acute myelogenous leukaemia following intensive chemotherapy. Br J Haematol 88: 332-7, 1994.
3. Carvalho de Sousa JP and Rastogi N. Comparative ability of human monocytes and macrophages to control the intracellular growth of Mycobacterium avium and Mycobacterium tuberculosis: effect of interferon-gamma and indomethacin. FEMS Microbiol Immunol 4: 329-34, 1992.
4. Thrasher AJ, Keep NH, Wientjes F, Segal AW. Chronic granulomatous disease [Review]. Biochim Biophys Acta 1227: 1-24, 1994.
5. Klebanoff SJ. Oxygen metabolism and the toxic properties of phagocytes [Review]. Ann Intern Med 93: 480-9, 1980.
6. Roilides E, Blake C, Holmes A, Pizzo PA, Walsh TJ. Granulocyte-macrophage colony-stimulating factor and interferon-gamma prevent dexamethasone-induced immunosuppression of antifungal monocyte activity against Aspergillus fumigatus hyphae. J Med Vet Mycol 34: 63-9, 1996.
7. Hogasen AK, Abrahamsen TG, Gaustad P. Various Candida and Torulopsis species differ in their ability to induce the production of C3, factor B and granulocyte-macrophage colony-stimulating factor (GM-CSF) in human monocyte cultures. J Med Microbiol 42: 291-98, 1995.
8. Yamamoto Y, Klein TW, Friedman H. Involvement of mannose receptor in cytokine interleukin-1 beta (IL-1beta), IL-6, and granulocyte-macrophage colony-stimulating factor responses, but not in chemokine macrophage inflammatory protein 1beta (MIP-1beta), MIP-2, and KC responses, caused by attachment of Candida albicans to macrophages. Infect Immun 65: 1077-82, 1997.
9. Holland SM. Host defense against nontuberculous mycobacterial infections [Review]. Semin Respir Infect 11: 217-30, 1996.
10. Fazal N. The role of reactive oxygen species (ROS) in the effector mechanisms of human antimycobacterial immunity. Biochem Mol Biol Int 43: 399-408, 1997.
11. Wassenaar TM, Engelskirchen M, Park S, Lastovica A. Differential uptake and killing potential of Campylobacter jejuni by human peripheral monocyte/macrophages. Med Microbiol Immunol 186: 139-44, 1997.
12. Chmiela M, Czkwianianc E, Wadstrom T, Rudnicka W. Role of Helicobacter pylori surface structures in bacterial interaction with macrophages. Gut 40: 20-4, 1997.
13. Keisari Y, Kabha K, Nissimov L, Schlepper-Schafer J, Ofek I. Phagocyte-bacteria interactions [Review]. Adv Dent Res 11: 43-9, 1997.
14. Liautard JP, Gross A, Dormand J, Kohler S. Interactions between professional phagocytes and Brucella spp [Review]. Microbiologia 12: 197-206, 1996.
15. Battistoni A, Donnarumma G, Greco R, Valenti P, Rotilio G. Overexpression of a hydrogen peroxide-resistant periplasmic Cu,Zn superoxide dismutase protects Escherichia coli from macrophage killing. Biochem Biophys Res Commun 243: 804-7, 1998.
16. Fernandex-Prada CM, Hoover DL, Tall BD, Venkatesan. Human monocyte-derived macrophages infected with virulent Shigella flexneri in vitro undergo a rapid cytolytic event similar to oncosis but not apoptosis. Infect Immun 65: 1486-96, 1997.
17. Durrbaum-Landmann I, Gercken J, Flad HD, Ernst M. Effect of in vitro infection of human monocytes with low numbers of Mycobacterium tuberculosis bacteria on monocyte apoptosis. Infect Immun 64: 5384-9, 1996.
18. Mattsson E, Van Dijk H, Verhoef J, Norrby R, Rollof J. Supernatants from Staphylococcus epidermidis grown in the presence of different antibiotics induce differential release of tumor necrosis factor alpha from human monocytes. Infect Immun 64:4351-5, 1996.
19. Schulze Jm Breitner-Ruddock S, von Briessen H, Brade V. High-and low-level cytokine induction in human peripheral blood mononuclear cells by different Borrelia burgdoferi strains. Med Microbiol Immunol 185: 31-7, 1996.
20. Cleveland MG, Gorham JD, Murphy TL, Tuomanen E, Murphy KM. Lipoteichoic acid preparations of gram-positive bacteria induce interleukin-12 through a CD14-dependent pathway. Infect Immun 64: 1906-12, 1996.
21. Dziarski R, Tapping RI, Tobias PS. Binding of bacterial peptidoglycan to CD14. J Biol Chem 273: 8680-90, 1998.
22. Boland A, Cornelis GR. Role of YopP in suppression of tumor necrosis factor alpha release by macrophages during Yersinia infection. Infect Immun 66: 1878-84, 1998.
23. Esser R, Glienke W, von Briesen H, Rubsamen-Waigmann H, Andreesen R. Differential regulation of proinflammatory and hematopoietic cytokines in human macrophages after infection with human immunodeficiency virus. Blood 88: 3474-81, 1996.
24. Canque B, Rosenzwajg M, Gey A, Tartour E, Fridman WH, Gluckman JC. Macrophage inflammatory protein-1alpha is induced by human immunodeficiency virus infection of monocyte-derived macrophages. Blood 87: 2011-9, 1996.
25. Holberg-Petersen M, Hogasen AK, Hogasen K, Abrahamsen TG, Degre M, Rollag H. Infection with human cytomegalovirus (HCMV) stimulates monocyte production of complement factor 3. Arch Virol 142: 689-98, 1997.
26. Badaro R, Nascimento C, Carvalho JS, Badaro F, Russo D, Ho JL, Reed SG, Johnson WD, Jones TC. Recombinant human granulocyte-macrophage colony-stimulating factor reverses neutropenia and reduces secondary infections in visceral leishmaniasis. J Infect Dis 170: 413-8, 1994.
27. Weiser WY, Van Neil A, Clark SC, David JR, Remold HG. Recombinant human granulocyte/macrophage colony-stimulating factor activates intracellular killing of Leishmania donovani by human monocyte-derived macrophages. J Exp Med 166: 1436-46, 1987.
28. Belosevic M, Davus CE, Meltzer MS, Nacy CA. Regulation of activated macrophage antimicrobial activities. Identification of lymphokines that cooperate with IFN-gamma for induction of resistance to infection. J Immunol 141: 890-6, 1988.
29. Badaro R, Nascimento C, Carvalho JS, Badaro F, Russo D, Ho JL, Reed SG, Johnson WD, Jones TC. Granulocyte-macrophage colony-stimulating factor in combination with pentavalent antimony for the treatment of visceral Leishmaniasis. Eur J Clin Microbiol Infect Dis 13: 23-8, 1994.
30. Hill AD, Naama HA, Gallagher HJ, Shou J, Calvano SE, Daly JM. Glucocorticoids mediate macrophage dysfunction in protein calorie malnutrition. Surgery 118: 130-6, 1995.
31. Yamamoto Y, Klein TW, Tomioka M, Friedman H. Differnential effects of granulocyte/macrophage colony-stimulating factor (GM-CSF) in enhancing macrophage resistance to Legionella pneumophila vs Candida albicans. Cell Immunol 176: 75-81, 1997.
32. Collins HL, Bancroft GJ. Cytokine enhancement of compement-dependent phagocytosis by macrophages: synergy of tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor for phagocytosis of Cryptococcus neoformans. Eur J Immunol 22: 1447-54, 1992.
33. Lechner AJ, Lamprech KE, Potthoff LH, Tredway TL, Matuschak GM. Recombinant GM-CSF reduces lung injury and mortality during neutropenic Candida sepsis. Am J Physiol 266: 561-8, 1994.
34. Vazquez-Torres A, Balish E, Macrophages in resistance to candidiasis [Review]. Microbiol Mol Biol Rev 61: 170-92, 1997.
35. Hebert JC, O'Reilly M, Barry B, Shatney L, Sartorelli K. Effects of exogenous cytokines on intravascular clearance of bacteria in normal and splenectomised mice. J Trauma 43: 875-9, 1997.
36. Williams MA, White SA, Miller JJ, Toner C, Withington S, Newland AC, Kelsey SM. Granulocyte-macrophage colony-stimulating factor induces activation and restores respiratory burst activity in monocytes from septic patients. J Infect Dis 177: 107-15, 1998.
37. Williams MA, Withington S, Newland AC, Kelsey SM. Monocyte anergy in septic shock is associated with a predilection to apoptosis and is reversed by granulocyte-macrophage colony-stimulating factor ex vivo. J Infect Dis (In Press), 1998.
38. Austin OM, Redmond HP, Watson WG, Cunney RJ, Grace PA, Bouchier-Hayes D. The beneficial effects of immuno-stimulation in posttraumatic sepsis. J Surg Res 59: 446-9, 1995.
39. Molloy RG, Holzheimer R, Nestor M, Collins K, Mannick JA, Rodrick ML. Granulocyte-macrophage colony-stimulating factor modulates immune function and improves survival after experimental thermal injury. Br J Surg 82: 770-6, 1995.
40. Toda H, Murata A, Oka Y, Uda K, Tanaka N, Ohashi I, Mori T, Matsuura N. Effect of granulocyte-macrophage colony-stimulating factor on sepsis-induced organ injury in rats. Blood 83: 2893-8, 1994.
41. Hebert JC and O'Reilly M. Granulocyte-macrophage colony-stimulating factor (GM-CSF) enhances pulmonary defences against pneumococcal infections after splenectomy. J Trauma 41: 663-6, 1996.
42. Hebert JC, O'Reilly M, Yuenger K, Shatney L, Yoder DW, Barry B. Augmentation of alveolar macrophage phagocytic activity by granulocyte colony stimulating factor and interleukin-1: influence of splenectomy. J Trauma 37: 909-12, 1994.
43. Sweeney JF, Rosemurgy AS, Wei S, Djeu JY. Candida antigen titer is a marker of neutrophil dysfunction after severe injury. J Trauma 36: 797-802, 1994.
44. Bermudez LE, Kemper CA, Deresinski SC. Dysfunctional monocytes from a patient with disseminated Mycobaterium kansassii infection are activated in vitro and in vivo by GM-CSF. Biotherapy 8: 135-42, 1994.
45. Bober LA, Grace MJ, Puglises-Sivo C, Rojas-Triana A, Sullivan LM, Narula SK. The effects of colony stimulating factors on human monocyte cell function. Int J Immunopharmacol 17: 385-92, 1995.
46. Murray HW, Carvia JS, Hariprashad J, Taylor AP, Stoeckle MY, Hockman H. Effect of granulocyte-macrophage colony-stimulating factor in experimental visceral leishmaniasis. J Clin Invest 95: 1183-92, 1995.
47. Offner F. Hematopoietic growth factors in cancer patients with invasive fungal infections [Review]. Eur J Microbiol Infect Dis 16: 56-63, 1997.
48. Peters BG, Adkins DR, Harrison BR, Velasquez WS, Dunphy FR, Petruska PJ, Bowers CE, Niemeyer R, McIntyre W, Vrahnos D, Auberry SE, Spitzer G. Antifungal effects of yeast-derived rhuGM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: a retrospective analysis. Bone Marrow Transplant 18: 93-102, 1996.
49. Roilides E, Holmes A, Blake C, Venzon D, Pizzo PA, Walsh TJ. Antifungal activity of elutriated human monocytes against Aspergillus fumigatus hyphae: enhancement by granulocyte-macrophage colony-stimulating factor and interferon-gamma. J Infect Dis 170: 894-9, 1994.
50. Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk HD, Kox W. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nature Medicine 3: 678-81. 1997.
51. Economopoulos T, Papageorgiou E, Stathakis N, Costantinidou M, Parharidou A, Kostourou A, Dervenoulas J, Raptis S. Treatment of high risk myelodysplastic syndromes with idarubicin and cytosine arabinoside supported by granulocyte-macrophage colony-stimulating factor (GM-CSF). Leuk Res 20: 385-90, 1996.
52. Rose C, Wattel E, Bastion Y, Berger E, Bauters F, Coiffier B, Fenaux P. Treatment with very low-dose GM-CSF in myelodysplastic syndromes with neutropenia. A report on 28 cases. Leukemia 8: 1458-62, 1994.
53. Maurer AB, Ganser A, Buhl R, Seipelt G, Ottmann OG, Mentzel U, Geissler RG, Hoelzer D. Restoration of impaired cytokine secretion from monocytes of patients with myelodysplastic syndromes after in vivo treatment with GM-CSF or IL-3. Leukemia 7: 1728-33, 1993.
54. Meropol NJ, Wood DE, Nemunaitis J, Petrelli NJ, Lipman BJ, Agosti JM, Whitmore JB. Randomised, placebo-controlled, multicentre trial of granulocyte-macrophage colony-stimulating factor as infection prophylaxis in oncologic surgery. Leukine Surgical Prophylaxis Group. J Clin Oncol 16: 1167-73, 1998.
55. Terashima T, Soejima K, Waki Y, Nakamura H, Fujishima S, Suzuki Y, Ishizaka A, Kanazawa M. Neutrophils activated by granulocyte colony-stimulating factor suppress tumor necrosis factor-alpha release from monocytes stimulated by endotoxin. Am J Respir Cell Mol Biol 13: 69-73, 1995.
56. El Habbal MH, Smith L, Elliot MJ, Strobel S. Effect of heparin anticoagulation on neutrophil adhesion molecules and release of IL-8:C3 is not essential. Cardiovasc Res 30: 676-81, 1995.
57. Waring PM, Presneill J, Maher DW, Layton JE, Cebon J, Waring LJ, Metcalf D. Differential alterations in plasma colony-stimulating factor concentrations in meningococcaemia. Clin Exp Immunol 102: 501-6. 1995.
58. Staveley-O'Carroll K, Sotomayor E, Montgomery J, Borrelo I, Hwang L, Fein S, Pardoll D, Levitsky H. Induction of antigen-specific T-cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci USA 95: 1178-83, 1998.
59. Chouaib S, Asselin-Paturel C, Mami-Chouaib F, Caignard A, Blay JY. The host tumor immune conflict: from immunosuppression to resistance and destruction [Review]. Immunol Today 18: 493-7, 1997.
60. Walker PR, Saas P, Dietrich PY. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back [Review], J Immunol 158: 4521-4, 1997.
61. Strand S, Galle PR. Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications [Review]. Mol Med Today 4: 63-8, 1998.
62. Dermine S, Mavroudis D, Jiang YZ, Hensel N, Molldrem J, Barrett AJ. Immune escape from a graft-versus-leukemia effect may play a role in the relapse of myeloid leukemias following allogeneic bone marrow transplantation. Bone Marrow Transplant 19: 989-99, 1997.
63. Powles R, Singhal S, Treleaven J, Kulkarni S, Horton C, Mehta J. Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation. Blood 91: 3481-6, 1998.
64. Papadopoulos EB, Carabasi MH, Castro-Malaspina H, Childs BH, Mackinnon S, Boulad F, Gillio AP, Kernan NA, Small TN, Szabolcs P, Taylor J, Yahalom J, Collins NH, Bleau SA, Black PM, Heller G, O'Reilly RJ. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host-disease. Blood 91: 1083-90, 1998.
65. Appelbaum FR. Graft versus leukemia (GVL) in the therapy of acute lymphoblastic leukemia (ALL) [Review]. Leukemia 11: 15-7, 1997.
66. Kolb HJ, Holler E. Adoptive immunotherapy with donor lymphocyte transfusions [Review], Curr Opin Oncol 9: 139-45, 1997.
67. Williams MA, Newland AC, Kelsey SM. Monocyte-mediated killing of human leukaemia is enhanced by administration of granulocyte-macrophage colony stimulating factor following chemotherapy. Brit J Haematol 98: 960-8, 1997.
68. Higuchi M, Aggarwal BB. Differential roles of the TNF receptor in TNF-induced cytotoxicity, DNA fragmentation and differentiation. J Immunol 152: 4017-22, 1994.
69. Cebon JS, Bury RW, Lieshchke GJ, Morsyn G. The effects of dose and route of administration on the pharmacokinetics of granulocyte-macrophage colony-stimulating factor. Eur J Cancer 26: 1064-69, 1990.
70. Nagler A, Shur I, Barak V, Fabian I. Granulocyte-macrophage colony-stimulating factor dependent monocyte-mediated cytotoxicity post-autologous transplantation. Leuk Res 20: 637-43, 1996.
71. Wiltchke C, Krainer M, Wagner A, Linkesch W, Zielinski CC. Influence of in vivo administration of GM-CSF and G-CSF on monocyte cytotoxicity. Exp Hematol 23: 402-6, 1995.
72. Wing EJ, Magee M, Whiteside T, Kaplan S, Shadduck R. Recombinant human granulocyte-macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of TNF and interferon in cancer patients. Blood 73: 643-6, 1989.
73. Chachoua A, Oratz R, Hoogmoed R, Caron D, Peace D, Liebes L, Blum RH, Vilcek J. Monocyte activation following systemic adminmistration of granulocyte-macrophage colony-stimulating factor J Immunother Emphasis Tumor Immunol 16: 132-41, 1994.
74. Charak BS, Agah R, Mazumder A. Granulocyte-macrophage colony-stimulating factor-induced antibody-dependent cellular cytotoxicity in bone marrow macrophages:application in bone marrow transplantation. Blood 81: 3474-9, 1993.
75. Wang BS, Lumanglas AL, Durr FE. Immunotherapy of a murine lymphoma by adoptive transfer of syngeneic macrophages activated with bisantrene. Cancer Res 46: 503-6, 1986.
76. Stevenson HC, Keenan AM, Woodhouse C, Ottow RT, Miller P, Steller EP, Foon KA, Abrams PG, Beman J, Larson SM. Fate of gamma-interferon-activated killer blood monocytes adoptively transferred into the abdominal cavity of patients with peritoneal carcinomatosis. Cancer Res 47: 6100-03, 1987.
77. Boccoli G, Masciulli R, Ruggeri EM, Carlini P, Giannella G, Montesoro E, Mastroberardino G, Isacchi G, Testa U, Calabresi F. Adoptive immunotherapy of human cancer: the cytokine cascade and monocyte actication following high-dose interleukin-2 bolus treatment. Cancer Res 50: 5795-800, 1990.
78. Bragger W, Scheibenbogen C, Krause S, Andreesen R. Large-scale production of human tumorcytotoxic macrophages grown from blood monocytes of cancer patients. Cancer Detect Prev 15: 407-12, 1991.
79. Faradji A, Bohbot A, Schmitt-Goguel M, Siffert JC, Dumont S, Wiesel ML, Piemont Y, Eischen A, Bergerat JP, Bartholeyns J. Large scale isolation of human blood monocytes by continuous flow centrifugation leukapheresis and counterflow centrifugation elutriation for adoptive cellular immunotherapy in cancer patients. J Immunol Methods 174: 297-309, 1994.
80. Inamura N, Sone S, Okubo A, Singh SM, Ogura T. Heterogeniety in response of human blood monocytes to granulocyte-macrophage colony-stimulating factor. J Leukoc Biol 47: 528-34, 1990.
81. Hennemann B, Beckman G, Eichelmann A, Rehm A, Andreesen R. Phase I trial of adoptive immunotherapy of cancer patients using monocyte-derived macrophages activated with interferon-gamma and lipopolysaccharide. Cancer Immunol Immunother 45: 250-6, 1998.
82. Hennemann B, Rehm A, Kottke A, Meidenbauer N, Andreesen R. Adoptive immunotherapy with tumor-cytotoxic macrophages derived from recombinant human granulocyte colony-stimulating factor (rhuGM-CSF) mobilised peripheral blood monocytes. J Immunother 20: 365-71. 1997.
83. Korbelik M, Naraparaju VR, Yamamoto N. Macrophage-directed immunotherapy as adjuvant to photodynamic therapy of cancer. Br J Cancer 75: 202-7, 1997.
84. Marienhagen J, Hennemann B, Andreesen R, Eilles C. 111In-oxine labelling of tumour-cytotoxic macrophages generated in vitro from circulating blood monocytes: an in vitro evaluation. Nucl Med Commun 16: 357-61, 1995.
85. Chokri M, Lopez M, Oleron C, Girard A, Martinache C, Canepa S, Siffert JC, Bartholeyns J. Production of human macrophages with potent antitumor properties (MAK) by culture of monocytes in the presence of GM-CSF and 1,25-dihydroxyvitamin D3. Anticancer Res 12: 2257-60, 1992.
86. Brenner MK, Rill DR, Holladay MS, Heslop HE, Moen RC, Buschle M, Krance RA, Santana VM, Anderson WF, Ihle JN. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet 343: 1134-37, 1993.
87. Brenner MK, Rill DR, Moen RC, Krance RA, Mirro J Jr., Anderson WF, Ihle JN. Gene marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 341: 85-86, 1993.
88. van de Loosedrecht AA, Ossenkoppele GJ. Beelan RH, Broekhoven MG, Schweitzer KM, Langenhuijsen MM. In vitro purging of clonogenic leukaemic cells from human bone marrow by interferon-gamma-activated monocytes. Cancer Immunol Immunother 38: 346-52, 1994.
89. Old LJ. Immunotherapy for cancer [Review]. Sci Am 275: 136-43, 1996.
90. Jager E, Ringhoffer M, Dienes HP, Arand M, Karbach J, Jager D, Ilsemann C, Hogerdorn M, Oesch F, Knuth A. Granulocyte-macrophage-colony stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 67: 54-62, 1996.
91. Fujimoto T, O,Donnell MA, Szilvasi A, Yang H, Duda RB. Baciluss-Calmette-Guerin plus interleukin-2 and/or granulocyte-macrophage colony stimulating factor enhances immunocompetent cell production of interferon-gamma, which inhibits B16F10 melanoma cell growth in vitro. Cancer Immunol Immunother 42: 280-4, 1996.
92. Disis ML, Bernhard H, Shiota FM, Hand SL, Gralow JR, Huseby ES, Gillis S, Cheever MA. Granulocyte-macrophage colony-stimulating factor:an effective adjuvant for protein and peptide-based vaccines. Blood 88: 202-10, 1996.
93. Kim CJ, Parkinson DR, Marincola F. Immunodominance across HLA polymorphism: implications for cancer immunotherapy [Review]. J Immunother 21: 1-16, 1998.
94. Chapuis F, Rosenzwajg M, Yagello M, Ekman M, Biberfeld P, Gluckman JC. Differentiation of human dendritic cells from monocytes in vitro Eur J Immunol 27: 431-41, 1997.
95. Girolomoni G, Riccardi-Castagnoli P. Dendritic cells hold promise for immunotherapy [Review]. Immunol Today 18: 102-04, 1997.
96. Steinmann RM. Dendritic cells and immune-based therapies [Review]. Exp Hematol 24: 859-62, 1996.
97. Barratt-Boyes SM, Henderson RA, Finn OJ. Chimpanzee dendritic cells with potent immunostimulatory function can be propagated from peripheral blood. Immunology 87: 528-34, 1996.
98. Christensen PJ, Armstron LR, Fak JJ, Chen GH, McDonald RA, Toews GB, Paine R. Regulation of rat pulmonary dendritic cell immunostimulatory activity by alveolar epithelial cell-derived granulocyte macrophage colony-stimulating factor. Am J Respir Cell Mol Biol 13: 426-33, 1995.
99. Tazi A, Bouchonnet F, Grandsaigne M, Boumsell L, Hance AJ, Soler P. Evidence that granulocyte-macrophage-colony stimulating factor regulates the distribution and differentiated state of dendritic cells/Langerhans cells in human lung and lung cancers. J Clin Invest 91: 566-76, 1993.
100. Krosl G, Korbelik M, Krosl J, Dougherty GJ. Potentiation of photodynamic therapy-elicited antitumor response by localized treatment with granulocyte-macrophage colony stimulating factor. Cancer Res 56: 3281-6, 1996.
101. Musiani P, Modesti A, Giovarelli M, Cavello F, Columbo MP, Lollini PL, Forni G. Cytokines, tumour-cell death and immunogenicity: a question of choice. Immunol Today 18: 32-36, 1997.
102. Hanania EG, Kavanagh J, Hortobagyi G, Giles, RE, Champlin R, Deisseroth AB. Recent advances in the application of gene therapy to human disease [Review]. Am J Med 99: 537-55, 1995.
103. Dilloo D, Bacon K, Holden W, Zhong W, Burdach S, Zlotnik A, Brenner M. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nature Med 2: 1090-1095, 1996.
104. Giboa E. Immunotherapy of cancer with genetically modified tumor vaccines [Review]. Semin Oncol 23: 101-7, 1996.
105. Schmidt-Wolf G, Schmidt-Wolf IG. Cytokines and clinical gene therapy. Eur J Immunol 25: 1137-40, 1995.
106. Ettinghousen SE, Rosenburg SA. Immunotherapy and gene therapy of cancer. Adv Surg 28: 223-54, 1995.
107. Armstrong CA, Botella R, Galloway TH, Murray N, Kramp JM, Song IS, Ansel JC. Antitumor effects of granulocyte-macrophage colony stimulating factor production by melanoma cells. Cancer Res 56: 2191-98, 1996.
108. Arca MJ, Krauss JC, Aruga A, Cameron MJ, Chang AE. Concurrent induction of CD4+ and CD8+ T cells during tumor growth with antitumor reactivity in adoptive immunotherapy. J Immunother 20: 138-45, 1997.
109. Ziegler-Heitbrock HW, Strobl M, Fingerle G et al. Small (CD14+/CD16+) monocytes and regular monocytes in human blood. Pathobiology 59: 127-30, 1991.
110. Ziegler-Heitbrock HW, Strobl M, Kieper D, et al. Differential expression of cytokines in human blood monocyte subpopulations. Blood 79: 503-11, 1992.
111. Fingerle G, Pforte A, Passlick B et al. The novel subset of CD14+/CD16+ blood monocytes is expanded in sepsis patients. Blood 82: 3170-6, 1993.
112. Ziegler-Heitbrock HW, Fingerle G, Strobel M et al. The novel subset of CD14+/CD16+ blood monocytes exhibit features of tissue macrophages. Eur J Immunol 23: 2053-8, 1993.
113. Otterlei M, Sundan A, Ryan L et al. Effects of anti-CD18 and LPS on CD14 expression on human monocytes. Scand J Immunol 41: 583-92, 1995.
114. Hamon G, Mulloy RH, Chen G et al. Transforming growth factor-beta 1 lowers the CD14 content of monocytes. J Surg Res 57: 574-8, 1994.
115. Frankenberger M, Sternsdorf T, Pechumer H et al. Differential cytokine expression in human blood monocyte subpopulations: a polymerase chain reaction analysis. Blood 87: 373-7, 1996.
116. Blumenstein M, Boekstegers P, Fraunberger P et al. Cytokine production precedes the expansion of CD14+CD16 monocytes in human sepsis: a case report of a patient with self-induced septicemia. Shock 8: 73-5, 1997.
117. Zheng M, Mrowietz U. Phenotypic differences between human blood monocyte subpopulations in psoriasis and atopic dermatitis. J Dermatol 24: 370-8, 1997.
118. Pulliam L, Gascon R, Stubblebine M, et al. Unique monocyte subset in patients with AIDS dementia. Lancet 349: 692-5, 1997.
119. Kampalath B, Cleveland RP, Kass L. Reduced CD4 and HLA-DR expression in neonatal monocytes. Clin Immunol Immunopathol 87: 93-100, 1998.
120. Ferrero E, Bondanza A, Leone BE et al. CD14+CD34+ peripheral blood mononuclear cells migrate across endothelium and give rise to immunostimulatory dendritic cells. J Immunol 160: 2675-83, 1998.
121. Palucka KA, Taquet N, Sanchez-Chapuis F et al. Dendritic cells as the terminal stage of monocyte differentiation. J Immunol 160: 4587-95, 1998.
122. Ziegler-Heitbrock HW. Heterogeneity of human blood monocytes: the CD14+ CD16+ subpopulation. Immunol Today. 17: 424-8, 1996.
123. Zheng M, Mrowietz U. Phenotypic differences between human blood monocyte subpopulations in psoriasis and atopic dermatitis. J Dermatol 24: 370-8, 1997.